Eliyahu Sharon Kalif
Net Worth
Last updated:
What is Eliyahu Sharon Kalif net worth?
The estimated net worth of Mr. Eliyahu Sharon Kalif is at least $12,593,307 as of 6 Mar 2024. He owns shares worth $3,564,593 as insider, has earned $1,948,714 from insider trading and has received compensation worth at least $7,080,000 in Teva Pharmaceutical Industries Limited.
What is the salary of Eliyahu Sharon Kalif?
Mr. Eliyahu Sharon Kalif salary is $1,770,000 per year as Executive Vice President & Chief Financial Officer in Teva Pharmaceutical Industries Limited.
How old is Eliyahu Sharon Kalif?
Mr. Eliyahu Sharon Kalif is 52 years old, born in 1973.
What stocks does Eliyahu Sharon Kalif currently own?
As insider, Mr. Eliyahu Sharon Kalif owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Teva Pharmaceutical Industries Limited (TEVA) | Executive Vice President & Chief Financial Officer | 203,691 | $17.5 | $3,564,593 |
What does Teva Pharmaceutical Industries Limited do?
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Eliyahu Sharon Kalif insider trading
Teva Pharmaceutical Industries Limited
Mr. Eliyahu Sharon Kalif has made 3 insider trades between 2021-2024, according to the Form 4 filled with the SEC. Most recently he sold 77,550 units of TEVA stock worth $1,048,088 on 6 Mar 2024.
The largest trade he's ever made was exercising 77,550 units of TEVA stock on 6 Mar 2024. As of 6 Mar 2024 he still owns at least 203,691 units of TEVA stock.
Teva Pharmaceutical Industries Limited key executives
Teva Pharmaceutical Industries Limited executives and other stock owners filed with the SEC:
- Dr. Hafrun Fridriksdottir (63) Executive Vice President of Global R&D
- Mr. Eliyahu Sharon Kalif (52) Executive Vice President & Chief Financial Officer
- Mr. Eric Drape (63) Executive Vice President of Global Operations
- Mr. Kare Schultz (64) Pres, Chief Executive Officer & Director